GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Total Tax Payable

Nyrada (ASX:NYR) Total Tax Payable : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Total Tax Payable?

Nyrada's Total Tax Payable for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Nyrada Total Tax Payable Historical Data

The historical data trend for Nyrada's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Total Tax Payable Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Total Tax Payable
- - - - -

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Tax Payable Get a 7-Day Free Trial - - - - -

Nyrada Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Nyrada Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Nyrada's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyrada (ASX:NYR) Business Description

Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines